Aurobindo Pharma Q1 FY26 PAT slips 10% YoY to Rs. 824 Cr

Aurobindo Pharma’s US formulations revenue slipped 1.9% on a year-on-year basis to Rs. 3,488 crore

Suraksha Diagnostic reports Q1 FY26 PAT higher by 20% at Rs. 9.1 Cr

Metropolis Healthcare reports Q1 FY26 PAT higher by 19% at Rs. 45 Cr

Biocon Q1 FY26 PAT slips 95% to Rs. 31.4 Cr

Revenue from operations rose 14.8 per cent year-on-year to Rs. 3,942 crore

Sandoz to acquire Just–Evotec Biologics facility for $300 million

The companies will now begin detailed contract negotiations and proceed with necessary consultations and approval processes

Aurobindo to acquire Lannett Company for Rs. 2,185 Cr

The transaction aligns with Aurobindo’s strategic objective to expand its U.S. manufacturing footprint by enhancing its existing domestic capabilities

Torrent Pharmaceuticals appoints Aman Mehta as MD

Aman holds a bachelor’s degree in economics from Boston University and an MBA from Columbia University, New York

Corona Remedies acquires 7 brands from Bayer's pharma division in India

This marks the fourth acquisition by Corona Remedies from multinational corporations

Senores Pharmaceuticals to increase stake in Havix

Havix is a US based company engaged in the business of developing, manufacturing and supplying of various finished formulations

Azelis acquires Azienda Chimica e Farmaceutica to expand presence in Italy

Azelis will strengthen its presence in the domestic market by leveraging portfolio synergies, actively consolidating the business, and creating value for all stakeholders